<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37327878</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>216</Volume><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5.</ArticleTitle><Pagination><StartPage>105654</StartPage><MedlinePgn>105654</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2023.105654</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(23)00132-8</ELocationID><Abstract><AbstractText>Enteroviruses (EV) cause a number of life-threatening infectious diseases. EV-D68 is known to cause respiratory illness in children that can lead to acute flaccid myelitis. Coxsackievirus B5 (CVB5) is commonly associated with hand-foot-mouth disease. There is no antiviral treatment available for either. We have developed an isoxazole-3-carboxamide analog of pleconaril (11526092) which displayed potent inhibition of EV-D68 (IC<sub>50</sub> 58 nM) as well as other enteroviruses including the pleconaril-resistant Coxsackievirus B3-Woodruff (IC<sub>50</sub> 6-20 nM) and CVB5 (EC<sub>50</sub> 1 nM). Cryo-electron microscopy structures of EV-D68 in complex with 11526092 and pleconaril demonstrate destabilization of the EV-D68 MO strain VP1 loop, and a strain-dependent effect. A mouse respiratory model of EV-D68 infection, showed 3-log decreased viremia, favorable cytokine response, as well as statistically significant 1-log reduction in lung titer reduction at day 5 after treatment with 11526092. An acute flaccid myelitis neurological infection model did not show efficacy. 11526092 was tested in a mouse model of CVB5 infection and showed a 4-log TCID<sub>50</sub> reduction in the pancreas. In summary, 11526092 represents a potent in vitro inhibitor of EV with in vivo efficacy in EV-D68 and CVB5 animal models suggesting it is worthy of further evaluation as a potential broad-spectrum antiviral therapeutic against EV.</AbstractText><CopyrightInformation>Copyright © 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Collaborations Pharmaceuticals Inc., Raleigh, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Jianing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherry</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular Biomedical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarbet</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT, USA; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurst</LastName><ForeName>Brett L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT, USA; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riabova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Research Center of Biotechnology RAS, 33-1 Leninsky prospect, 119071, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazakova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research Center of Biotechnology RAS, 33-1 Leninsky prospect, 119071, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egorova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center of Biotechnology RAS, 33-1 Leninsky prospect, 119071, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Penny</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leser</LastName><ForeName>J Smith</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, Infectious Disease, Medicine and Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudy</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyler</LastName><ForeName>Kenneth L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Veterans Affairs, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klose</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volobueva</LastName><ForeName>Alexandrina S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Saint Petersburg Pasteur Institute, 14 Mira Street, 197101, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belyaevskaya</LastName><ForeName>Svetlana V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Saint Petersburg Pasteur Institute, 14 Mira Street, 197101, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarubaev</LastName><ForeName>Vladimir V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Saint Petersburg Pasteur Institute, 14 Mira Street, 197101, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makarov</LastName><ForeName>Vadim</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Research Center of Biotechnology RAS, 33-1 Leninsky prospect, 119071, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekins</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Collaborations Pharmaceuticals Inc., Raleigh, NC, USA. Electronic address: sean@collaborationspharma.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN272201700060C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI011219</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS102164</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R44 GM122196</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9H4570Q89D</RegistryNumber><NameOfSubstance UI="C115201">pleconaril</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000629404">acute flaccid myelitis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Coxsackievirus B5</Keyword><Keyword MajorTopicYN="N">Cryo-electron microscopy</Keyword><Keyword MajorTopicYN="N">EV-D68</Keyword><Keyword MajorTopicYN="N">Enteroviruses</Keyword></KeywordList><CoiStatement>Declaration of competing interest SE is owner, TRL is an employee at Collaborations Pharmaceuticals, Inc. SE and VM are co-inventors on a patent submitted for 11526092. All other co-authors have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>17</Day><Hour>5</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37327878</ArticleId><ArticleId IdType="mid">NIHMS1910275</ArticleId><ArticleId IdType="pmc">PMC10527014</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2023.105654</ArticleId><ArticleId IdType="pii">S0166-3542(23)00132-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abzug MJ, Cloud G, Bradley J, Sanchez PJ, Romero J, Powell D, Lepow M, Mani C, Capparelli EV, Blount S, Lakeman F, Whitley RJ, Kimberlin DW, National Institute of, A., Infectious Diseases Collaborative Antiviral Study, G., 2003. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J 22, 335–341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690273</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH, 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213–221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreoni AR, Colton AS, 2017. Coxsackievirus B5 associated with hand-foot-mouth disease in a healthy adult. JAAD Case Rep 3, 165–168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5376252</ArticleId><ArticleId IdType="pubmed">28413820</ArticleId></ArticleIdList></Reference><Reference><Citation>Aradottir E, Alonso EM, Shulman ST, 2001. Severe neonatal enteroviral hepatitis treated with pleconaril. Pediatr Infect Dis J 20, 457–459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11332680</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya SC, 1998. Japanese encephalitis virus and poliomyelitis-like illness. Lancet 351, 1964.</Citation><ArticleIdList><ArticleId IdType="pubmed">9654295</ArticleId></ArticleIdList></Reference><Reference><Citation>Bratslavska O, Platace D, Miklasevics E, Fuchs D, Martinsons A, 2007. Influence of neopterin and 7,8-dihydroneopterin on the replication of Coxsackie type B5 and influenza A viruses. Med Microbiol Immunol 196, 23–29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16868770</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun H, Makarov VA, Riabova OB, Wutzler P, Schmidtke M, 2011. Amino Acid Substitutions At Residue 207 of Viral Capsid Protein 1 (VP1) Confer Pleconaril Resistance in Coxsackievirus B3 (CVB3). Antiviral Research 90, A54–A55.</Citation></Reference><Reference><Citation>Carta A, Sanna G, Briguglio I, Madeddu S, Vitale G, Piras S, Corona P, Peana AT, Laurini E, Fermeglia M, Pricl S, Serra A, Carta E, Loddo R, Giliberti G, 2018. Quinoxaline derivatives as new inhibitors of coxsackievirus B5. Eur J Med Chem 145, 559–569.</Citation><ArticleIdList><ArticleId IdType="pubmed">29339251</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC, 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66, 12–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow M, Newman JF, Filman D, Hogle JM, Rowlands DJ, Brown F, 1987. Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature 327, 482–486.</Citation><ArticleIdList><ArticleId IdType="pubmed">3035380</ArticleId></ArticleIdList></Reference><Reference><Citation>Diana GD, Rudewicz P, Pevear DC, Nitz TJ, Aldous SC, Aldous DJ, Robinson DT, Draper T, Dutko FJ, Aldi C, et al., 1995. Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem 38, 1355–1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">7731021</ArticleId></ArticleIdList></Reference><Reference><Citation>Dienz O, Rincon M, 2009. The effects of IL-6 on CD4 T cell responses. Clin Immunol 130, 27–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2660866</ArticleId><ArticleId IdType="pubmed">18845487</ArticleId></ArticleIdList></Reference><Reference><Citation>Dienz O, Rud JG, Eaton SM, Lanthier PA, Burg E, Drew A, Bunn J, Suratt BT, Haynes L, Rincon M, 2012. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol 5, 258–266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328598</ArticleId><ArticleId IdType="pubmed">22294047</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A, Ekins S, Schmidtke M, Makarov V, 2019. Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. Eur J Med Chem 178, 606–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194503</ArticleId><ArticleId IdType="pubmed">31226653</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A, Kazakova E, Jahn B, Ekins S, Makarov V, Schmidtke M, 2020. Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. Eur J Med Chem 188, 112007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7002245</ArticleId><ArticleId IdType="pubmed">31881489</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K, 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486–501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans WJ, Hurst BL, Peterson CJ, Van Wettere AJ, Day CW, Smee DF, Tarbet EB, 2019. Development of a respiratory disease model for enterovirus D68 in 4-week-old mice for evaluation of antiviral therapies. Antiviral Res 162, 61–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6997929</ArticleId><ArticleId IdType="pubmed">30521834</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields BN, Knipe DM, Howley PM, Griffin DE, 2007. Fields Virology, 5th ed. Wolters Kluwer Health/Lippincott Williams &amp; Wilkins, Philadelphia.</Citation></Reference><Reference><Citation>Filman DJ, Syed R, Chow M, Macadam AJ, Minor PD, Hogle JM, 1989. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J 8, 1567–1579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400988</ArticleId><ArticleId IdType="pubmed">2548847</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Samuels O, Rich MM, 2002. Poliomyelitis due to West Nile virus. N Engl J Med 347, 1280–1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">12270972</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC, 2003. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 74, 525–535.</Citation><ArticleIdList><ArticleId IdType="pubmed">14663455</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M, Pleconaril Respiratory Infection Study, G., 2003. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 36, 1523–1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfferich J, Knoester M, Van Leer-Buter CC, Neuteboom RF, Meiners LC, Niesters HG, Brouwer OF, 2019. Acute flaccid myelitis and enterovirus D68: lessons from the past and present. Eur J Pediatr 178, 1305–1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6694036</ArticleId><ArticleId IdType="pubmed">31338675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixon AM, Clarke P, Tyler KL, 2017. Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68-Associated Paralytic Myelitis. J Infect Dis 216, 1245–1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853295</ArticleId><ArticleId IdType="pubmed">28968718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogle JM, Chow M, Filman DJ, 1985. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229, 1358–1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">2994218</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm-Hansen CC, Midgley SE, Fischer TK, 2016. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis 16, e64–e75.</Citation><ArticleIdList><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF, 1999. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 341, 936–942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst BL, Evans WJ, Smee DF, Van Wettere AJ, Tarbet EB, 2019. Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice. Virology 526, 146–154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309259</ArticleId><ArticleId IdType="pubmed">30390563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A, 2009. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 206, 79–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626661</ArticleId><ArticleId IdType="pubmed">19139171</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura T, Oshitani H, 2015. Erratum: Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev Med Virol 25, 268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738597</ArticleId><ArticleId IdType="pubmed">26151890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv LB, Donlin LT, 2014. Regulation of type I interferon responses. Nat Rev Immunol 14, 36–49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Pillai PS, 2014. Innate immunity to influenza virus infection. Nat Rev Immunol 14, 315–328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104278</ArticleId><ArticleId IdType="pubmed">24762827</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoester M, Helfferich J, Poelman R, Van Leer-Buter C, Brouwer OF, Niesters HGM, Group, E.-D.A.W., 2019. Twenty-nine Cases of Enterovirus-D68-associated Acute Flaccid Myelitis in Europe 2016: A Case Series and Epidemiologic Overview. Pediatr Infect Dis J 38, 16–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6296836</ArticleId><ArticleId IdType="pubmed">30234793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauder SN, Jones E, Smart K, Bloom A, Williams AS, Hindley JP, Ondondo B, Taylor PR, Clement M, Fielding C, Godkin AJ, Jones SA, Gallimore AM, 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur J Immunol 43, 2613–2625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3886386</ArticleId><ArticleId IdType="pubmed">23857287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, Wang SM, Su IJ, Wang JR, Yeh TM, Chen SH, Yu CK, 2005. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 86, 3263–3269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, Baggen J, Meng G, Xiao C, Thibaut HJ, van Kuppeveld FJ, Rossmann MG, 2015a. Sialic acid-dependent cell entry of human enterovirus D68. Nat Commun 6, 8865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660200</ArticleId><ArticleId IdType="pubmed">26563423</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, Fokine A, Meng G, Shin WH, Long F, Kuhn RJ, Kihara D, Rossmann MG, 2015b. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science 347, 71–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4307789</ArticleId><ArticleId IdType="pubmed">25554786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, Patel NR, Klena JD, Nichol ST, Cihlar T, Zaki SR, Feldmann H, Spiropoulou CF, de Wit E, 2019. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6732787</ArticleId><ArticleId IdType="pubmed">31142680</ArticleId></ArticleIdList></Reference><Reference><Citation>Loddo R, Novelli F, Sparatore A, Tasso B, Tonelli M, Boido V, Sparatore F, Collu G, Delogu I, Giliberti G, La Colla P, 2015. Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. Bioorg Med Chem 23, 7024–7034.</Citation><ArticleIdList><ArticleId IdType="pubmed">26443549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C, Li AP, 2001. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 134, 271–281.</Citation><ArticleIdList><ArticleId IdType="pubmed">11336975</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma KC, Winn A, Moline HL, Scobie HM, Midgley CM, Kirking HL, Adjemian J, Hartnett KP, Johns D, Jones JM, Lopez A, Lu X, Perez A, Perrine CG, Rzucidlo AE, McMorrow ML, Silk BJ, Stein Z, Vega E, New Vaccine Surveillance Network, C., Hall AJ, 2022. Increase in Acute Respiratory Illnesses Among Children and Adolescents Associated with Rhinoviruses and Enteroviruses, Including Enterovirus D68 - United States, July-September 2022. MMWR Morb Mortal Wkly Rep 71, 1265–1270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9541033</ArticleId><ArticleId IdType="pubmed">36201400</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmstrom K, Pitkaranta A, Carpen O, Pelkonen A, Malmberg LP, Turpeinen M, Kajosaari M, Sarna S, Lindahl H, Haahtela T, Makela MJ, 2006. Human rhinovirus in bronchial epithelium of infants with recurrent respiratory symptoms. J Allergy Clin Immunol 118, 591–596.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin JA, Messacar K, Yang ML, Maloney JA, Lindwall J, Carry T, Kenyon P, Sillau SH, Oleszek J, Tyler KL, Dominguez SR, Schreiner TL, 2017. Outcomes of Colorado children with acute flaccid myelitis at 1 year. Neurology 89, 129–137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501931</ArticleId><ArticleId IdType="pubmed">28615421</ArticleId></ArticleIdList></Reference><Reference><Citation>Matz J, 2013. Vapendavir significantly improves upper respiratory symptoms of naturally acquired rhinovirus infection in asthmatic adults: Results of a phase 2 clinical trial. Eur Respir J 42, 1493.</Citation></Reference><Reference><Citation>Melnick JL, 1997. Poliovirus and other enteroviruses, in: Evans AS, Kaslow RA (Eds.), Viral infections of humans: epidemiology and control. Plenum Publishing, New York, pp. 583–663.</Citation></Reference><Reference><Citation>Messacar K, Asturias EJ, Hixon AM, Van Leer-Buter C, Niesters HGM, Tyler KL, Abzug MJ, Dominguez SR, 2018. Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality. Lancet Infect Dis 18, e239–e247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778404</ArticleId><ArticleId IdType="pubmed">29482893</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Sillau S, Hopkins SE, Otten C, Wilson-Murphy M, Wong B, Santoro JD, Treister A, Bains HK, Torres A, Zabrocki L, Glanternik JR, Hurst AL, Martin JA, Schreiner T, Makhani N, DeBiasi RL, Kruer MC, Tremoulet AH, Van Haren K, Desai J, Benson LA, Gorman MP, Abzug MJ, Tyler KL, Dominguez SR, 2019. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology 92, e2118–e2126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512883</ArticleId><ArticleId IdType="pubmed">30413631</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller EK, Lu X, Erdman DD, Poehling KA, Zhu Y, Griffin MR, Hartert TV, Anderson LJ, Weinberg GA, Hall CB, Iwane MK, Edwards KM, New Vaccine Surveillance, N., 2007. Rhinovirus-associated hospitalizations in young children. J Infect Dis 195, 773–781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109786</ArticleId><ArticleId IdType="pubmed">17299706</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens DM, Folkers GK, Fauci AS, 2019. Acute Flaccid Myelitis: Something Old and Something New. mBio 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6445942</ArticleId><ArticleId IdType="pubmed">30940708</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehlenbachs A, Bhatnagar J, Zaki SR, 2015. Tissue tropism, pathology and pathogenesis of enterovirus infection. J Pathol 235, 217–228.</Citation><ArticleIdList><ArticleId IdType="pubmed">25211036</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS, Maher K, Schnurr D, Flemister MR, Lovchik JC, Peters H, Sessions W, Kirk C, Chatterjee N, Fuller S, Hanauer JM, Pallansch MA, 2004. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol 85, 2577–2584.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302951</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang IK, Ichinohe T, Iwasaki A, 2013. IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8(+) T cell responses to influenza A virus. Nat Immunol 14, 246–253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577947</ArticleId><ArticleId IdType="pubmed">23314004</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul AV, Schultz A, Pincus SE, Oroszlan S, Wimmer E, 1987. Capsid protein VP4 of poliovirus is N-myristoylated. Proc Natl Acad Sci U S A 84, 7827–7831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299409</ArticleId><ArticleId IdType="pubmed">2825164</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE, 2004. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25, 1605–1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS, 2005. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 49, 4492–4499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1280128</ArticleId><ArticleId IdType="pubmed">16251287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear DC, Tull TM, Seipel ME, Groarke JM, 1999. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43, 2109–2115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Platania-Solazzo A, Field TM, Blank J, Seligman F, Kuhn C, Schanberg S, Saab P, 1992. Relaxation therapy reduces anxiety in child and adolescent psychiatric patients. Acta Paedopsychiatr 55, 115–120.</Citation><ArticleIdList><ArticleId IdType="pubmed">1585802</ArticleId></ArticleIdList></Reference><Reference><Citation>Potterton L, Agirre J, Ballard C, Cowtan K, Dodson E, Evans PR, Jenkins HT, Keegan R, Krissinel E, Stevenson K, Lebedev A, McNicholas SJ, Nicholls RA, Noble M, Pannu NS, Roth C, Sheldrick G, Skubak P, Turkenburg J, Uski V, von Delft F, Waterman D, Wilson K, Winn M, Wojdyr M, 2018. CCP4i2: the new graphical user interface to the CCP4 program suite. Acta Crystallogr D Struct Biol 74, 68–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947771</ArticleId><ArticleId IdType="pubmed">29533233</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhl AC, Gomes GF, Damasceno S, Fritch EJ, Levi JA, Johnson NJ, Scholle F, Premkumar L, Hurst BL, Lee-Montiel F, Veras FP, Batah SS, Fabro AT, Moorman NJ, Yount BL, Dickmander RJ, Baric RS, Pearce KH, Cunha FQ, Alves-Filho JC, Cunha TM, Ekins S, 2022. Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice. ACS Omega 7, 31935–31944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454268</ArticleId><ArticleId IdType="pubmed">36097511</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA, 2017. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 14, 290–296.</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H, 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27, 493–498.</Citation></Reference><Reference><Citation>Renois F, Leveque N, Deliege PG, Fichel C, Bouin A, Abely M, N'Guyen Y, Andreoletti L, 2013. Enteroviruses as major cause of microbiologically unexplained acute respiratory tract infections in hospitalized pediatric patients. J Infect 66, 494–502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172623</ArticleId><ArticleId IdType="pubmed">23542784</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG, 1994. Viral cell recognition and entry. Protein Sci 3, 1712–1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142612</ArticleId><ArticleId IdType="pubmed">7849588</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG, et al., 1985. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317, 145–153.</Citation><ArticleIdList><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart HA, 2000. Antiviral therapy for enteroviruses and rhinoviruses. Antivir Chem Chemother 11, 261–271.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950388</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart HA, Webster AD, Pleconaril Treatment Registry, G., 2001. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 32, 228–235.</Citation><ArticleIdList><ArticleId IdType="pubmed">11170912</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH, Chen S, 2012. Prevention of overfitting in cryo-EM structure determination. Nat Methods 9, 853–854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4912033</ArticleId><ArticleId IdType="pubmed">22842542</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz N, Kurrer M, Bachmann MF, Kopf M, 2005. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol 79, 6441–6448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1091664</ArticleId><ArticleId IdType="pubmed">15858027</ArticleId></ArticleIdList></Reference><Reference><Citation>Senior K, 2002. FDA panel rejects common cold treatment. Lancet Infect Dis 2, 264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sin J, Mangale V, Thienphrapa W, Gottlieb RA, Feuer R, 2015. Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis. Virology 484, 288–304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4567421</ArticleId><ArticleId IdType="pubmed">26142496</ArticleId></ArticleIdList></Reference><Reference><Citation>Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW, 2016. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res 131, 61–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100981</ArticleId><ArticleId IdType="pubmed">27063860</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele MT, Walsh I, 2015. Commentary. Severe Respiratory Illness Associated With Enterovirus D68-Missouri and Illinois, 2014. Ann Emerg Med 65, 335.</Citation><ArticleIdList><ArticleId IdType="pubmed">25702181</ArticleId></ArticleIdList></Reference><Reference><Citation>Suloway C, Pulokas J, Fellmann D, Cheng A, Guerra F, Quispe J, Stagg S, Potter CS, Carragher B, 2005. Automated molecular microscopy: the new Leginon system. J Struct Biol 151, 41–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15890530</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurman AR, Anderson S, Doncel GF, 2014. Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics. Am J Reprod Immunol 71, 523–530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083564</ArticleId><ArticleId IdType="pubmed">24521428</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A, Franco D, Tucker S, Hilgenfeld R, Froeyen M, Leyssen P, Neyts J, 2014. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother 58, 6990–6992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Toivonen L, Schuez-Havupalo L, Karppinen S, Teros-Jaakkola T, Rulli M, Mertsola J, Waris M, Peltola V, 2016. Rhinovirus Infections in the First 2 Years of Life. Pediatrics 138.</Citation><ArticleIdList><ArticleId IdType="pubmed">27581858</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokarz R, Firth C, Madhi SA, Howie SRC, Wu W, Sall AA, Haq S, Briese T, Lipkin WI, 2012. Worldwide emergence of multiple clades of enterovirus 68. J Gen Virol 93, 1952–1958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542132</ArticleId><ArticleId IdType="pubmed">22694903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Robertson DH, Brooks CL 3rd, Vieth M, 2003. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 24, 1549–1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925999</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang ML, Wang CT, Yang SJ, Leu CH, Chen SH, Wu CL, Shiau AL, 2017. IL-6 ameliorates acute lung injury in influenza virus infection. Sci Rep 7, 43829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338329</ArticleId><ArticleId IdType="pubmed">28262742</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, Shi D, Fu J, Zhang L, Chen R, Zheng B, Wang X, Xu S, Zhu L, Wang K, 2022. Atomic Structures of Coxsackievirus B5 Provide Key Information on Viral Evolution and Survival. J Virol 96, e0010522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9093117</ArticleId><ArticleId IdType="pubmed">35442060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y, Hu W, Yao K, 2012. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol 157, 669–679.</Citation><ArticleIdList><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Q, Yang Z, Liu Y, Deng H, Xiao H, Shi L, He J, 2009. Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo. Arch Virol 154, 601–607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7086808</ArticleId><ArticleId IdType="pubmed">19291363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>